Stockscreener 앱 받기
644.47
0.81%
-5.29
Regeneron Pharmaceuticals Inc 주식(REGN)의 최신 뉴스
Jim Cramer on Regeneron: “There Could Be Some More Downgrades” - Insider Monkey
CytomX Therapeutics to Present at Upcoming June Investor Conferences - GlobeNewswire Inc.
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron backed Parabilis Medicines seeks U.S. IPO - Seeking Alpha
REGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud - Business Wire
After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets - Yahoo Finance
Tredje AP fonden Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Resona Asset Management Co. Ltd. Has $24.71 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
ProShare Advisors LLC Has $142.25 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Fideuram Intesa Sanpaolo Private Banking S.P.A. Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Harvest Portfolios Group Inc. Has $63.10 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Scotiabank Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Maintains Target Price $770 - Moomoo
Research Alert: CFRA Lowers Rating On Shares Of Regeneron Pharmaceuticals, Inc To Hold From Buy - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Regeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2B - Yahoo Finance
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry? - Yahoo Finance Singapore
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Melanoma Trial Setback And Share Price Pullback - Yahoo Finance
Regeneron Stock Tumbles 12% After Experimental Cancer Drug Misses Key Trial Goal - TIKR.com
REGN Maintained by Canaccord Genuity -- Price Target Lowered to $875 - GuruFocus
Canaccord Genuity Group Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $875.00 - MarketBeat
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $770 to $968 - Moomoo
REGN SHAREHOLDER INVESTIGATION: SueWallSt Investigates Regeneron Pharmaceuticals for Possible Securities Law Violations – Company AnnouncementFT.com - Financial Times
Why Regeneron Pharmaceuticals (REGN) Is Down 11.7% After Key Melanoma Combo Trial Missed Its Goal - Yahoo Finance
Canaccord lowers Regeneron stock price target on pipeline concerns By Investing.com - Investing.com Canada
Regeneron teams up with Parabilis to advance novel antibody Helicon - The Pharma Letter
UnitedHealth, Regeneron slip premarket; Dominion Energy, Delta Air Lines jump - Investing.com
Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates - Pharmaceutical Technology
North Dakota State Investment Board Acquires Shares of 3,579 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Inc stock (US7739031091): strategic Parabilis deal after REGN sell-off - AD HOC NEWS
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Handelsbanken Fonder AB - MarketBeat
Citigroup downgrades Regeneron Pharmaceuticals (REGN) - MSN
Regeneron Melanoma Setback And New Collaboration Reshape Oncology Outlook - simplywall.st
UnitedHealth, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sahm
Could Cash Machine Regeneron Pharmaceuticals Stock Be Your Next Buy? - Trefis
Between Incyte and Regeneron Pharmaceuticals, Which Stock Looks Set to Break Out? - Trefis
Wolfe Research lowers Regeneron stock price target to $860 on LAG-3 miss By Investing.com - Investing.com Australia
Regeneron stock sinks after cancer trial miss prompts selloff - TechStock²
Regeneron Pharma Update Signals New Market Watchpoint - Kalkine Media
Regeneron Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Regeneron Pharmaceuticals (REGN) - PR Newswire
Regeneron Partners With Parabilis To Reach Undruggable Targets - Citeline News & Insights
Wolfe Research lowers Regeneron stock price target to $860 on LAG-3 miss - Investing.com Nigeria
Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck’s Keytruda - Barron's
Investigation launched into Regeneron over misleading trial optimism and stock drop - Pluang
U.S. Indexes Finished Mixed Monday As Cognizant Tech Solutions Led, Regeneron Pharmaceuticals Lagged - Barron's
Wolfe Research Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $860 - Moomoo
Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock. - Barchart.com
Why Regeneron (REGN) Shares Are Trading Lower Today - The Globe and Mail
Regeneron stock drops double digits on oncology trial failure - TradingView
REGN Downgraded by Citigroup -- Price Target Lowered to $700 - GuruFocus
REGN Maintained by Truist Securities -- Price Target Lowered to $778 - GuruFocus
Regeneron's Late-Stage Melanoma Study Misses Primary Goal - Yahoo Finance
Leerink cuts Regeneron stock rating on melanoma drug failure By Investing.com - Investing.com Australia
REGN Maintained by BMO Capital -- Price Target Lowered to $730 - GuruFocus
BMO Capital Markets Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $730.00 - MarketBeat
Regeneron Pharmaceuticals Inc Stock (REGN) Moved Down by 10.44% on May 18: Facts Behind the Movement - TradingKey
Cantor Fitzgerald cuts Regeneron stock price target to $785 on trial failure - Investing.com UK
Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Gap Down After Analyst Downgrade - MarketBeat
Regeneron Pharmaceuticals (REGN) Faces Setback in Melanoma Trial Results - GuruFocus
Regeneron Faces Nasdaq Composite Heat After Downgrade - Kalkine Media
Truist Financial Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
REGN Maintained by RBC Capital -- Price Target Lowered to $707 - GuruFocus
Regeneron: Time To Forget Fianlimab (Rating Upgrade) (NASDAQ:REGN) - Seeking Alpha
Regeneron’s fianlimab lags in melanoma, does $2.3B deal with Parabilis - BioWorld News
REGN Maintained by JP Morgan -- Price Target Lowered to $850 - GuruFocus
Regeneron Pharmaceuticals Trial Miss May Raise Broader Strategy Questions, RBC Says - Moomoo
Micron, Regeneron, UnitedHealth, Dominion Energy, Ford, Tesla, Lumentum, and More Movers - Barron's
Regeneron (REGN) Faces Setback in Melanoma Drug Trial Results - GuruFocus
0.65%
0.05%
자본화:
|
볼륨(24시간):